Favipiravir
Article Sidebar
Published:
May 6, 2021
Keywords:
favipiravir avigan influenza antiviral agent
Main Article Content
Abstract
-
Article Details
Section
Interesting Drugs
References
1. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci [Internet]. 2017 [cited 2021 Feb 24]; 93(7):449-63. Figure1, Chemical structure of Favipiravir; p. 450. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713175/pdf/pjab-93-449.pdf
2. Avigan tablet 200 mg (Favipiravir) [Internet]. 2017 [cited 2021 Jan 8]. Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw.
3. Favipiravir (United States: not commercially available; refer to prescribing and access restrictions): drug information. Uptodate [Internet]. 2021[cited 2021 Jan 8]. Available from: https://www.uptodate.com/contents/favipiravir-united-states-not-commercially-available-refer-to-prescribing-and-access-restrictions-drug-information.
4. Department of Disease Control. Guidelines for diagnosis, treatment and prevention in hospital of Coronavirus disease (COVID-19) [Internet]. 2020 [cited 2021 Jan 8]. Available form: https://ddc.moph.go.th/viralpneumonia/file/g_health_care/g04_CPG111263.pdf
5. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71.
6. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oselta-mivirmonotherapy in critically ill patients with influenza virus infection. J Infect Dis 2020;221:1688–98.
7 Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; 6:1192-8.
8. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial [Internet]. 2020[cited 2021 Jan 8]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4.full.pdf.
9. Doi Y, Kondo M, Matsuyama A, Ando M, Kuwatsuka Y, Ishihara T. Preliminary report of the Favipiravir observational study in Japan (2020/5/15) [Internet]. 2020 [cited 2021 Jan 8]. Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
10. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother [Internet]. 2020 [cited 2021 Jan 8]; 64(12):e01897-20. Available from: https://aac.asm.org/content/64/12/e01897-20.long
11. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real- world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multicenter observational study [Internet]. 2020 [cited 2021 Jan 8]. Available from: https://www.medrxiv.org/content/10.1101/2020.06.24.20133249v2.full-text.
2. Avigan tablet 200 mg (Favipiravir) [Internet]. 2017 [cited 2021 Jan 8]. Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw.
3. Favipiravir (United States: not commercially available; refer to prescribing and access restrictions): drug information. Uptodate [Internet]. 2021[cited 2021 Jan 8]. Available from: https://www.uptodate.com/contents/favipiravir-united-states-not-commercially-available-refer-to-prescribing-and-access-restrictions-drug-information.
4. Department of Disease Control. Guidelines for diagnosis, treatment and prevention in hospital of Coronavirus disease (COVID-19) [Internet]. 2020 [cited 2021 Jan 8]. Available form: https://ddc.moph.go.th/viralpneumonia/file/g_health_care/g04_CPG111263.pdf
5. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71.
6. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oselta-mivirmonotherapy in critically ill patients with influenza virus infection. J Infect Dis 2020;221:1688–98.
7 Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020; 6:1192-8.
8. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial [Internet]. 2020[cited 2021 Jan 8]. Available from: https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4.full.pdf.
9. Doi Y, Kondo M, Matsuyama A, Ando M, Kuwatsuka Y, Ishihara T. Preliminary report of the Favipiravir observational study in Japan (2020/5/15) [Internet]. 2020 [cited 2021 Jan 8]. Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
10. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother [Internet]. 2020 [cited 2021 Jan 8]; 64(12):e01897-20. Available from: https://aac.asm.org/content/64/12/e01897-20.long
11. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real- world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multicenter observational study [Internet]. 2020 [cited 2021 Jan 8]. Available from: https://www.medrxiv.org/content/10.1101/2020.06.24.20133249v2.full-text.